Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: EN Paris
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

TNG:FP

7.2600 EUR 0.00000.00%

As of 11:35:00 ET on 01/30/2015.

Snapshot for Transgene SA (TNG)

Open: 7.2600 Day's Range: 7.0600 - 7.2700 Volume: 42,962
Previous Close: 7.2600 52wk Range: 6.2000 - 13.7100 1-Yr Rtn: -41.50%

Stock Chart for TNG

No chart data available.
  • TNG:FP 7.2600
  • 1D
  • 1M
  • 1Y
7.2600
Interactive TNG Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for TNG

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. CAC -
Earnings Per Share (EUR) (ttm) -1.2419
Est. EPS (EUR) (12/2014) -1.2440
Est. PEG Ratio -
Market Cap (M EUR) 279.70
Shares Outstanding (M) 38.53
30 Day Average Volume 58,656
Price/Book (mrq) 2.9540
Price/Sale (ttm) 67.1577
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/24/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for TNG

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for TNG

Transgene S.A. is a biotechnology company. The Company develops vaccines against cancer and infectious diseases. Transgene has products under development for lung, kidney, prostate and colorectal cancers, cutaneous T-cell lymphoma, hepatitis C, malignant melanoma, and muscular dystrophy.

Philippe ArchinardChairman/CEOEric QuemeneurExec VP/VP:Research & Dev
Stephane BoisselExecutive Vice PresidentLaurence BertaudDir:Human Resources
More Company Profile & Key Executives for TNG

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil